key: cord-0791595-wm4hcio5
authors: Sen-Crowe, Brendon; McKenney, Mark; Elkbuli, Adel
title: Medication shortages during the COVID-19 pandemic: Saving more than COVID lives
date: 2020-07-24
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2020.07.044
sha: acc21720e7251a517396db88756a5d670a644464
doc_id: 791595
cord_uid: wm4hcio5

nan

In the United States (US) alone, 3, 302, 194 cases and 135,171 deaths due to COVID-19 have been confirmed as of July 12 th , 2020. 1 To put this in perspective, from 2018-2019, the CDC estimated there were approximately 35,500,000 cases and 34,200 deaths due to influenza. 2 These statistics correspond to a case-fatality ratio (CFR), the number of deaths divided by the total number of confirmed cases, that is nearly 40 times that of influenza in the case of COVID-19 (CFR 0.1% and 4.0%, respectively). Over the course of the pandemic, hospital resources have become scarce. Shortages of PPE, healthcare personnel, and ventilators have been reported nationwide, now add medications to the list of shortages. [3] [4] [5] From 2015-2019, annual medication shortages have increased consistently from 5 to 31 ( Figure  1 ). However, over the span of only 6 months, 27 new shortages were announced in 2020. 6 Medication shortages in 2020 have reached 87% that of the shortages reported in 2019 in half of the time. When considering the effect of the second wave of COVID-19 cases it is likely that medication shortages will continue to escalate.

J o u r n a l P r e -p r o o f One report of 44,672 confirmed cases of COVID-19 suggests 6,168 (14%) patients suffer from severe hypoxic respiratory failure and 2,087 (5%) required mechanical ventilation. 7 In the case of ventilation, patients often require varying amounts of sedation and/or analgesia depending on their status. For example, fentanyl is a commonly used drug for analgesia, whereas propofol is used for sedation. In addition, midazolam can be infused if heavy sedation is required. 8 These medications are essential not patient comfort and to minimize the risk of self extubation. Yet, all 3 of these medications are currently in shortage (Table 1) .

There is concern for additional patients presenting to emergency departments as states commit to reopening. One analysis suggests that the number of motor vehicle collisions (MVCs) decreased during the pandemic. 9 It is likely that the number of MVCs will return to baseline levels as additional states commit to reopening. The additional stress from trauma-related cases on the healthcare system in the midst of preexisting medication shortages could result in deaths that may have been preventable if ample medications were available.

Furthermore, medication shortages pose a threat to many more patients beyond those infected with COVID-19. For example, hydroxychloroquine and chloroquine are used for many autoimmune diseases such as rheumatoid arthritis. Although the shortages of these medications have recently resolved, 6 other drugs such as dexamethasone used to treat both COVID-19 and many other diseases is depleting (Table 1) .

With so much coverage on the pandemic, it is easy to forget about patients presenting with other common diseases. For example, heart disease remains the leading cause of death in the US and translates to 1 in every 4 deaths. 10 There is a shortage of medications used to treat those with cardiovascular disease, such as furosemide and labetalol injections (Table 1) . Similarly, drugs used to prevent blood clots, such as heparin, are also currently in shortage (Table 1 ).

In addition, medication shortages will likely have an effect on cancer patients. Shortages of drugs used for medical imaging of cancer, such as Technetium, have the potential to compound the decrease in diagnoses due to the pandemic (Table 1) . Furthermore, shortages of oncology medications that provide a protective effect from other chemotherapy agents, such as amifostine, may increase the risk for adverse events and worsen patient outcomes.

It is possible that as some medication shortages resolve, other shortages will arise and increase mortality. In 2017, over 1.7 million deaths were due to the top 5 causes of death: heart disease, cancer, unintentional injuries, chronic lower respiratory diseases, and stroke. 11 The medication shortages reported by the FDA thus far impact all 5 leading causes of death and could have a significant impact on the mortality rate. It is important for us to take proactive measures in order to minimize the negative effects on the nation. 

COVID-19 Map. Johns Hopkins Coronavirus Resource Center

Medical Visits, Hospitalizations, and Deaths in the United States -2018-2019 influenza season

Strategies to Mitigate Healthcare Personnel Staffing Shortages

Strategies to Optimize the Supply of PPE and Equipment

Ventilator Stockpiling and Availability in the US. Johns Hopkins Center for Health Security

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

COVID-19 Impact on drugs essential for ventilator use

Vehicle related injury patterns during the COVID-19 pandemic: What has changed?

Leading Causes of Death

J o u r n a l P r e -p r o o f